O72.0 Insurance Policy Changes

ICD-10 O72.0 is officially defined as "Third-stage hemorrhage." code O72.0 is referenced in 5 tracked payer policy changes from Aetna, Blue Cross & Blue Shield of Mississippi, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code O72.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Sep 29, 2026Medium impact
Autotransfusers and Red Blood Cell Genotyping (CPB 0639, reviewed 2026-09-09)
Aetna considers autotransfusion and cell saver devices medically necessary for emergency or intra-operative autotransfusion, hemodilution or cell washing autotransfusion, and post-operative autotransfusion (usually done within 2 hours with a chest tube collection device) after heart surgery and traumatic hemithorax. Aetna considers these devices experimental, investigational, or unproven for all other indications, and not medically necessary for procedures expected to require less than 2 units of blood. Red cell genotyping is medically necessary for sickle cell disease, thalassemia, hemoglobinopathies, recurring transfusions, post-transfusion hemolysis with no detectable antibodies, autoimmune hemolytic anemia, multiple transfusions, positive direct antiglobulin test, certain pregnancies, hemolytic disease of the fetus and newborn, and conflicting serological antibody results, while hypoxic red blood cells are considered experimental, investigational, or unproven for improving energy metabolism and post-transfusion recoveries.
Aetna · Identified Aug 12, 2026Medium impact
Autotransfusers and Red Blood Cell Genotyping (CPB 0639, reviewed 2025-12-11)
Aetna Clinical Policy Bulletin 0639 covers autotransfusers and cell saver devices, and red blood cell genotyping. Aetna considers autotransfusion medically necessary for emergency or intra-operative autotransfusion, hemodilution or cell washing autotransfusion, and post-operative autotransfusion (usually done within 2 hours with a chest tube collection device) that re-infuses blood after heart surgery and traumatic hemithorax, and considers it experimental, investigational or unproven for all other indications. Autotransfusion and cell saver devices are not considered medically necessary for procedures expected to require less than 2 units of blood. Red cell genotyping is medically necessary for individuals with sickle cell disease, thalassemia syndromes, hemoglobinopathies or other conditions requiring recurring transfusions, post-transfusion hemolysis with no detectable antibodies, autoimmune hemolytic anemia, multiple transfusions or a positive direct antiglobulin test, and in the other situations the policy lists, while hypoxic red blood cells are considered experimental for improving energy metabolism and post-transfusion recoveries.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Occlusion of Uterine Arteries Using Transcatheter Embolization
Transcatheter embolization of uterine arteries is considered medically necessary as a treatment of uterine fibroids or as a treatment of postpartum uterine hemorrhage. One repeat transcatheter embolization of uterine arteries to treat persistent fibroid symptoms after an initial uterine artery embolization may be considered medically necessary. Transcatheter embolization for cervical ectopic pregnancy, uterine arteriovenous malformation and adenomyosis is considered investigational.
Independence Blue Cross · Identified Jun 25, 2026Low impact
11.06.04k, Uterine Artery Embolization
Independence Blue Cross has reissued Policy 11.06.04k with no substantive changes to coverage criteria for uterine artery embolization (UAE). The policy maintains its existing position: UAE is covered for symptomatic uterine fibroids and postpartum hemorrhage, with specific medical necessity criteria. No workflow changes are required for billing operations.
Independence Blue Cross · Identified Jun 19, 2026Low impact
11.06.04k, Uterine Artery Embolization
Independence Blue Cross has reissued Policy 11.06.04k on Uterine Artery Embolization (UAE) with no substantive changes to coverage criteria, medically necessary indications, contraindications, or experimental/investigational designations. The policy continues to cover UAE for symptomatic uterine fibroids and postpartum hemorrhage under specified clinical criteria, with no new billing code, documentation, or prior authorization requirements.

Watch O72.0

Get one email when a payer policy names O72.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code O72.0?

There are 5 tracked policy changes affecting code O72.0, including updates from Aetna, Blue Cross & Blue Shield of Mississippi, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code O72.0?

Payers that have issued tracked updates for code O72.0 include: Aetna, Blue Cross & Blue Shield of Mississippi, Independence Blue Cross.

How do I get notified when code O72.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code O72.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code O72.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Autotransfusers and Red Blood Cell Genotyping (CPB 0639, reviewed 2026-09-09)

Autotransfusers and Red Blood Cell Genotyping (CPB 0639, reviewed 2025-12-11)

Occlusion of Uterine Arteries Using Transcatheter Embolization

11.06.04k, Uterine Artery Embolization

11.06.04k, Uterine Artery Embolization

What insurance policy changes affect code O72.0?

Which payers have updated policy for code O72.0?

How do I get notified when code O72.0 policy changes?

Why do payers change policies for code O72.0?